Mabwell and Calico Announce Licensing Deal for IL-11 Monoclonal Antibody

On June 26, 2025, a significant partnership was announced between Mabwell (Shanghai) Bioscience Co., Ltd., a forward-thinking biopharmaceutical company, and Calico Life Sciences LLC, a biotechnology organization committed to tackling aging and diseases related to aging. This collaboration is centered around an exclusive licensing agreement for IL-11 directed therapeutics, including 9MW3811, a monoclonal antibody currently in Phase I trials.

Mabwell has made notable strides in researching the potential of 9MW3811 for treating age-related diseases. It has conducted Phase I clinical trials for this antibody in both China and Australia. Additionally, 9MW3811 has received approval to initiate a Phase I trial in the United States. Through this agreement, Mabwell will provide Calico with exclusive rights to further develop, manufacture, and market 9MW3811 across all territories except for Greater China.

Mabwell, listed on the Shanghai Stock Exchange (688062.SH), is renowned for its innovative approach within the biopharmaceutical sector. The company spans the entire pharmaceutical value chain, aiming to deliver more effective and affordable treatments that address global medical demands. Mabwell primarily focuses on oncology and diseases associated with aging. The company's mission is encapsulated in the phrase "Explore Life, Benefit Health," and its vision emphasizes the transformation of innovative ideas into tangible realities.

Calico Life Sciences LLC, founded by Alphabet Inc. and led by Arthur D. Levinson, Ph.D., is dedicated to advancing the understanding of biological processes underlying human aging. By leveraging cutting-edge technologies and model systems, Calico strives to develop interventions that promote extended and healthier lifespans.

This collaboration between Mabwell and Calico represents a promising advance in the field of biotechnology. By combining Mabwell's research capabilities and experience with Calico's innovative approach to age-related diseases, the partnership seeks to unlock new therapeutic possibilities. The exclusive rights granted to Calico will enable the company to harness its expertise and resources to bring 9MW3811 to a broader market, potentially transforming the landscape of age-related treatments.

The agreement underscores the importance of cross-border collaborations in the pharmaceutical industry. As the global population ages, there is an increasing demand for innovative therapies to address age-related health challenges. The partnership between Mabwell and Calico exemplifies a strategic alliance that leverages complementary strengths in pursuit of a common goal: improving health outcomes and enhancing the quality of life for individuals affected by diseases of aging.

Looking ahead, the development and commercialization of 9MW3811 by Calico, with Mabwell retaining rights in Greater China, could lead to significant advancements in the treatment of age-related conditions worldwide. This alliance highlights the potential of biopharmaceutical innovations to create meaningful impacts on global health, paving the way for future breakthroughs in the field.